Sumitomo Pharma Canada announced that ORGOVYX (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer. The availability of ORGOVYX follows the Health Canada approval of ORGOVYX in October 2023 for the treatment of advanced prostate cancer.

"Lowering the body's testosterone level is a first-line treatment approach for men with advanced prostate cancer," said Fred Saad, M.D., FRCS, Professor and Chairman of the Department of Surgery and Director of Genitourinary Oncology at the University of Montreal. "Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares."

The Health Canada approval of ORGOVYX was based on efficacy and safety data from the Phase 3 HERO study in men with advanced prostate cancer.

"An estimated 24,700 Canadian men were diagnosed with prostate cancer last year, making the disease the most common cancer experienced by men in the country," said Lisa Mullett, SVP, General Manager of Sumitomo Pharma Canada, Inc.

"With the availability of ORGOVYX as of today, we are pleased to offer Canadian physicians an oral GnRH antagonist treatment option with proven safety and tolerability for their patients with advanced prostate cancer."